Business
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 3962F Angle PLC 29 October 2018 \n\n\n\n\nFor immediate release\n\n\n 29 October 2018\n\n\n\n \nANGLE plc (\"the Company\")\n \nPARSORTIX DEMONSTRATES CAPABILITY TO HARVEST FETAL CELLS FROM THE BLOOD OF PREGNANT WOMEN FOR NON-INVASIVE PRENATAL TESTING (NIPT)\n \nParsortix system offers potential to greatly extend current NIPT applicability to a wide range of conditions not currently feasible with existing techniques \n \nCommercialisation discussions initiated with corporate partners\n \nResults presented at 6th Annual Advances in Prenatal Diagnostics conference\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from a pilot study to investigate the potential of ANGLE's ParsortixTM system to harvest fetal cells from the peripheral blood of pregnant women for the detection of fetal abnormalities. The results are being presented today at the 6th Annual Advances in Prenatal Diagnostics conference in Cambridge, Massachusetts. \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"Non-invasive prenatal testing is a major new market for the Parsortix system and a potential solution to the current limitations of NIPT, providing a more comprehensive diagnosis of fetal abnormalities for mothers at risk of an affected pregnancy. ANGLE's product-based approach to liquid biopsy enables us to leverage partnerships with third parties, which we are developing in the NIPT space, an established and fast growing large scale market.\"\n \n \nIn recent years, NIPT, based on a simple blood test for the mother, has emerged as the preferred method of testing prenatal fetal health in place of the traditional invasive chorionic villi sampling (CVS) and amniocentesis procedures. Over the next year, the NHS plans to roll out NIPT to women identified as having a high risk of an affected pregnancy.\n \nHowever, current NIPT has two key limitations. First and foremost, NIPT is currently based on analysis of cell-free fetal DNA (fragments of dead fetal cells) which is limited to testing for chromosomal disorders that are caused by the presence of an extra or missing copy (aneuploidy) of a chromosome. These include trisomy 21 (Down's syndrome) and a s...